China's Shanghai Pharmaceuticals sales revenues 2019, by product
In 2019, Shanghai Pharmaceutical Group Co., Ltd. generated around 1.53 trillion yuan of sulfotanshinone sodium injection. It was the best-selling product of the company with a gross profit of around 1044 million yuan. The enterprise is one of the largest national pharmaceutical groups in China which owns over 1,700 pharmacies.